Therefore, we aimed to compare the efficacy of different EGFR‐TKIs in de novo T790M mutation‐positive (T790M+) NSCLC patients to identify an alternative therapeutic strategy for the de novo T790M mutation. This evidence concerns the gene EGFR and non-small cell lung carcinoma.